Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | An insight into response criteria for Waldenström’s macroglobulinemia

Steven Treon • 28 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into current response criteria for Waldenström’s macroglobulinemia (WM) and the importance of improving these in the future. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Steven Treon

1:59
Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon • 29 Sep 2023
2:23
Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon • 29 Sep 2023
1:54
Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon • 29 Sep 2023
1:47
Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors
Steven Treon • 29 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals